(Albany, US) DelveInsight has launched a new report on Epithelial Ovarian Cancer Market Insights, Epidemiology, and Market Forecast-2030.
DelveInsight’s ” Epithelial Ovarian Cancer Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Epithelial Ovarian Cancer, historical and forecasted epidemiology as well as the Epithelial Ovarian Cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Some of Epithelial Ovarian Cancer Facts:
Request for Free Sample Report: https://www.delveinsight.com/sample-request/epithelial-ovarian-cancer-market
Scope of Epithelial Ovarian Cancer Report:
Ovarian cancer is a group of diseases that originates in the ovaries, or in the related areas of the fallopian tubes and the peritoneum. It is one of the most common gynecologic cancers, and one of the leading causes of cancer-associated female mortality in the world. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.
Epithelial ovarian tumors develop from the cells that cover the outer surface of the ovary. Most epithelial ovarian tumors are benign. There are several types of benign epithelial tumors, including serous adenomas, mucinous adenomas, and Brenner tumors. Cancerous epithelial tumors are carcinomas – meaning they begin in the tissue that lines the ovaries.
There are some ovarian epithelial tumors whose appearance under the microscope does not clearly identify them as cancerous and they are called borderline tumors or tumors of low malignant potential (LMP tumors).
Epithelial cancer of the ovary is thought to derive from malignant transformation of the epithelium of the ovarian surface, peritoneum, or fallopian tube. The exact molecular transformation events causing EOC are not known. Studies have shown that epigenetic phenomenon may also play a role. Mutations of the oncogenes HER2, C-myc, K-ras, Akt, and the tumor suppressor gene p53 have been observed.
The clinical presentation of EOC can either be acute or subacute. Acute cases present with conditions such as pleural effusion, small bowel obstruction and venous thromboembolism.
Subacute cases may present with non specific symptoms such as abdominal fullness, bloating, an adnexal mass, vague pelvic or abdominal pain and gastrointestinal symptoms.
During the last decade it has become apparent that EOC encompasses 5 distinct diseases, with different presentations (age of development, distribution of disease), response to chemotherapy, prognosis, molecular features, and site of origin. While these carcinomas share a common site of tumor growth in the ovary, they represent diverse diseases entities. This has driven the move towards more histotype specific management strategies.
Some of Epithelial Ovarian Cancer Companies:
Epithelial Ovarian Cancer Drugs Covered:
Table of Contents:
1. Key Insights
2. Executive Summary of Epithelial Ovarian Cancer
3. Competitive Intelligence Analysis for Epithelial Ovarian Cancer
4. Epithelial Ovarian Cancer: Market Overview at a Glance
5. Epithelial Ovarian Cancer: Disease Background and Overview
6. Patient Journey
7. Epithelial Ovarian Cancer Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Epithelial Ovarian Cancer Treatment
11. Marketed Products
12. Emerging Therapies
13. Epithelial Ovarian Cancer: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Epithelial Ovarian Cancer
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +19193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/epithelial-ovarian-cancer-market